Synthesis and biological evaluation of 2,5-diaryl-1,3,4-oxadiazole derivatives as novel Src homology 2 domain-containing protein tyrosine phosphatase 2 (SHP2) inhibitors
作者:Xiang-Dong Meng、Li-Xin Gao、Zhi-Jia Wang、Bo Feng、Chun Zhang、Rajendran Satheeshkumar、Jia Li、Yun-Long Zhu、Yu-Bo Zhou、Wen-Long Wang
DOI:10.1016/j.bioorg.2021.105384
日期:2021.11
target for novel anti-cancer agents. Although significant progress has been made in identifying chemotypes of SHP2 inhibitors, these specific compounds might not be clinically useful to inhibit frequently encountered mutated SHP2 variants. Consequently, it is highly desirable to develop chemically different SHP2 inhibitors sensitive to SHP2 mutants. This work developed a new type of SHP2 inhibitors with
Src homology-2 domain contains-protein tyrosine phosphatase-2 (SHP2) 是致癌细胞信号级联反应的汇聚节点,包括 PD-L1/PD-1 通路。作为一种癌蛋白和潜在的免疫调节剂,SHP2 现在已成为新型抗癌药物的有吸引力的靶点。尽管在鉴定 SHP2 抑制剂的化学型方面取得了重大进展,但这些特定化合物可能在临床上无法用于抑制经常遇到的突变 SHP2 变体。因此,非常需要开发对 SHP2 突变体敏感的化学上不同的 SHP2 抑制剂。这项工作开发了一种具有 2,5-二芳基-1,3,4-恶二唑支架的新型 SHP2 抑制剂。代表性化合物6l表现出SHP2抑制活性,IC 502.73 ± 0.20 µM,SHP2 的选择性分别比 SHP1、PTP1B 和 TCPTP 高 1.56 倍、5.26 倍和 7.36 倍。进一步的研究证实,6l表现为对白血病细胞